CAS

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
CAS, Blood vessel, National coverage determination, Stroke, Medical Affairs Bureau, Nine Months, Medicare, TEL, NCD, NSPR, Global marketing, IDE, Quality assurance, EPS, CEA, Clinical trial, Risk, Myocardial infarction, Medicaid, TCAR, Center for Medicare and Medicaid Innovation, Safety, Stenosis, Investment, Patient, Death, CMS, Birth control, Medical device, Clothing, Cryptocurrency, Pharmaceutical industry, Beauty salon, Video game, Film industry, MD

TEL AVIV, Israel and MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke today announced financial results and business updates for the third quarter ended September 30, 2023.

Key Points: 
  • Generated CGuard revenue for the third quarter 2023 of $1,556,072, an 8.8 % increase over the same period in 2022.
  • Sold 2,734 CGuard EPS stent systems in the third quarter of 2023, as compared to 2,624 in the third quarter of 2022, an increase of 4.2 %.
  • Total financial income for the third quarter of 2023 was $461,000, an increase of $380,000 or 469% compared to $81,000 for the third quarter of 2022.
  • Management will host a conference call today, Monday, November 6th, at 8:30 AM ET, to review financial results and provide an update on corporate developments.

T1 E1 Network Test Solution Capabilities

Retrieved on: 
Thursday, November 2, 2023
CAS, DCE, Linux, PC, WCS, DTE, GSM, Analyser, Command-line interface, SSH, FXS, GL, Telephone, Python, Unix, WLC, PPP, Maintenance, USB, Frame Relay, SS7, Microsoft Windows, Telecom, PowerShell, ISDN, SS1, FXO, Probe, Collection, HDLC, Automation, Data analysis, Communication, Console, Emulation, Mobile phone, Video game, Internet service provider, Computer data storage, Computer network

“GL's tProbe™ is a test and measurement device for T1 E1 networks.

Key Points: 
  • “GL's tProbe™ is a test and measurement device for T1 E1 networks.
  • GL's Windows Client/Server (WCS) software allows T1 E1 analysis and emulation cards with remote operation, automation, and multi-site connectivity capabilities.
  • It sends commands to T1 E1 WCS servers and shows the responses in Console, PowerShell, or Terminal Windows.
  • Available with Dual T1 or E1, FXO, FXS, DTE and DCE interfaces
    Bit Error Rate Testing over all timeslots.

Antibody-Drug Conjugates: IP and R&D Trends to Inform Innovation, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 2, 2023
ROI, CAS, Information scientist, ADC, Intellectual property, IP, Patent, Spacecraft, Research, R, Therapy, Freedom, Fine chemical

TORONTO, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into advancements in antibody-drug conjugates (ADCs) and related patent filings. Antibody-drug conjugates are among the most promising drug classes in oncology. The ADC research landscape is rapidly evolving, driven by advancements in antibody engineering, linker technology, payload development and diversification and more.

Key Points: 
  • In this free webinar, learn about the evolving global research and intellectual property (IP) landscape of antibody-drug conjugates (ADCs).
  • The featured speakers will discuss strategies for a comprehensive IP search to inform investment and protect innovations.
  • TORONTO, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into advancements in antibody-drug conjugates (ADCs) and related patent filings.
  • Join this webinar to gain insights into the latest trends in antibody-drug conjugate innovation and the complications of understanding the IP landscape in this area.

China Power (02380.HK) Shows Hard Power in Energy Transition with 6 Original Technology Achievements

Retrieved on: 
Tuesday, October 31, 2023
Digital, CAS, Hidili Industry International Development Limited, Policy, SPIC, Chinese Academy of Engineering, PV, CEC, News, Carbon, Wind, Acquisition, Chinese Communist Party Committee Secretary, Internet, University of the Chinese Academy of Sciences, Politics, Transport, CAE, New energy, CNY, AI, China Power Clean Energy Development, Renewable energy, Management, China Power

The forum focused on two themes, "ensuring energy security and driving future energy development with innovation", exploring development paths for energy transition and sustainable development.

Key Points: 
  • The forum focused on two themes, "ensuring energy security and driving future energy development with innovation", exploring development paths for energy transition and sustainable development.
  • At the forum, China Power launched six technological innovations that are highly representative of the industry and lead the trend of industrial transformation.
  • As disclosed in the half-yearly report 2023, China Power has a consolidated installed capacity of 32,941.2 MW, with clean energy (hydropower, wind power, solar power, gas power and biomass power) accounting for 66.35%, a significant increase of 15.6% year on year.
  • While China Power continues to lead the industry in the clean energy market, it is also actively returning to its shareholders.

AM Best to Participate in Series of Sessions at Casualty Actuarial Society’s Annual Meeting

Retrieved on: 
Thursday, October 26, 2023
Insurance, Professional Services, CAS, Westin Bonaventure Hotel, AM Best, Complex, ChatGPT, News, AM, Council for Scientific and Industrial Research – Ghana, PST, Risk management, COVID-19, Casualty, ALL, Associate, Industry loss warranty

AM Best will participate in a variety of sessions at the Casualty Actuarial Society’s (CAS) Annual Meeting, which will take place Nov. 5-8, 2023, in Los Angeles.

Key Points: 
  • AM Best will participate in a variety of sessions at the Casualty Actuarial Society’s (CAS) Annual Meeting, which will take place Nov. 5-8, 2023, in Los Angeles.
  • Tom Mount, senior director, AM Best, will discuss the year-end 2022 reserve positions of the U.S. property/casualty segment.
  • Sridhar Manyem, senior director, Industry Research and Public Relations, AM Best, will speak at two sessions.
  • This year’s annual meeting will take place at The Westin Bonaventure Hotel & Suites in Los Angeles.

T3 E3 Signal Analyzer for Channelized and Unchannelized Applications

Retrieved on: 
Wednesday, October 18, 2023
CAS, KBPS, Graphical user interface, ATM, Aeropuerto T1-T2-T3 (Madrid Metro), DS1, Human, GL, Fraction, DSU, Subrat Sahoo, Single-board computer, PPP, USB, Plesiochronous digital hierarchy, Frame Relay, Software, SS7, Support, PDH, Estrone, Technics Digital Link, Adtran, Data-rate units, ISDN, DS3, Algorithm, HDLC, Video game, Medical imaging, Internet service provider, Channelization (telecommunications)

GL's T3 E3 Analyzer is a versatile tool that handles signaling, voice, and data in full T3 (DS3) or E3 data streams.

Key Points: 
  • GL's T3 E3 Analyzer is a versatile tool that handles signaling, voice, and data in full T3 (DS3) or E3 data streams.
  • This analyzer is equipped for both Unchannelized (Unstructured) and Channelized (Structured) T3 E3 Traffic,” said Vijay Kulkarni, CEO of GL Communications.
  • GL also offers T3 E3 probe and rack-mount variants, combining the USB-based T3 E3 Analyzer hardware unit with a Single Board Computer pre-installed with all software and licenses.
  • The T3 E3 hardware platform with associated T1 E1 Send Receive Server and Channelized T3 analyzer software can transmit T1 E1 frames over T3 E3 lines and capture, record, and monitor multiple T1 or E1 channels over Channelized T3 or E3 links.

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth of the Healthcare Industry

Retrieved on: 
Friday, October 20, 2023
CAS, Health, Vaccine, Construction, Aggregation, Entrepreneurship, University of the Chinese Academy of Sciences, Multilateralism, Chemical physics, Expo, Pharmaceutical industry

In recent years, Taizhou has set its sights on the goal of achieving a healthcare industry scale of 40 billion yuan by 2025, according to Taizhou Medical High-Tech Zone (Gaogang District). Emulating top domestic and international biopharmaceutical industry clusters, it has focused on constructing a distinctive "3+2" industrial system, with a primary focus on the three key pillars of biopharmaceuticals, new chemical drug formulations, in vitro diagnostic reagents, and high-end medical equipment. Additionally, they are committed to enhancing two distinctive industries -- special medical formula foods and animal healthcare products. Presently, the China Medical City has brought together over 1,300 healthcare companies, submitted applications for more than 2,100 pharmaceutical innovations, and attracted over 4,300 high-level talents for entrepreneurship. Taizhou has also become the exclusive pilot zone for the aggregation and development of the healthcare industry along the Yangtze Economic Belt and a pilot zone for the development of new vaccines and specific diagnostic reagents.

Key Points: 
  • TAIZHOU, China, Oct. 20, 2023 /PRNewswire/ -- On October 19, the 14th China (Taizhou) International Medical Expo commenced at the China Medical City Convention Trade Center.
  • Themed "Innovation Empowers the Construction of a Large Health Industry Ecosystem", this edition of the Medical Expo gathered nearly 130 industry experts from around the world.
  • Together, they collaborated to contribute to the development of Taizhou's healthcare industry, empowering Taizhou to establish itself as a global leader in the pharmaceutical and healthcare sector.
  • Throughout the duration of the Medical Expo, a total of 19 specialized events covering areas such as biopharmaceuticals, medical devices, health services, and international cooperation will invite participation from the public.

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth of the Healthcare Industry

Retrieved on: 
Friday, October 20, 2023
CAS, Health, Vaccine, Construction, Aggregation, Entrepreneurship, University of the Chinese Academy of Sciences, Multilateralism, Chemical physics, Expo, Pharmaceutical industry

In recent years, Taizhou has set its sights on the goal of achieving a healthcare industry scale of 40 billion yuan by 2025, according to Taizhou Medical High-Tech Zone (Gaogang District). Emulating top domestic and international biopharmaceutical industry clusters, it has focused on constructing a distinctive "3+2" industrial system, with a primary focus on the three key pillars of biopharmaceuticals, new chemical drug formulations, in vitro diagnostic reagents, and high-end medical equipment. Additionally, they are committed to enhancing two distinctive industries -- special medical formula foods and animal healthcare products. Presently, the China Medical City has brought together over 1,300 healthcare companies, submitted applications for more than 2,100 pharmaceutical innovations, and attracted over 4,300 high-level talents for entrepreneurship. Taizhou has also become the exclusive pilot zone for the aggregation and development of the healthcare industry along the Yangtze Economic Belt and a pilot zone for the development of new vaccines and specific diagnostic reagents.

Key Points: 
  • TAIZHOU, China, Oct. 20, 2023 /PRNewswire/ -- On October 19, the 14th China (Taizhou) International Medical Expo commenced at the China Medical City Convention Trade Center.
  • Themed "Innovation Empowers the Construction of a Large Health Industry Ecosystem", this edition of the Medical Expo gathered nearly 130 industry experts from around the world.
  • Together, they collaborated to contribute to the development of Taizhou's healthcare industry, empowering Taizhou to establish itself as a global leader in the pharmaceutical and healthcare sector.
  • Throughout the duration of the Medical Expo, a total of 19 specialized events covering areas such as biopharmaceuticals, medical devices, health services, and international cooperation will invite participation from the public.

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth of the Healthcare Industry

Retrieved on: 
Friday, October 20, 2023
CAS, Health, Vaccine, Aggregation, Entrepreneurship, University of the Chinese Academy of Sciences, Multilateralism, Chemical physics, Expo, Pharmaceutical industry

In recent years, Taizhou has set its sights on the goal of achieving a healthcare industry scale of 40 billion yuan by 2025, according to Taizhou Medical High-Tech Zone (Gaogang District). Emulating top domestic and international biopharmaceutical industry clusters, it has focused on constructing a distinctive "3+2" industrial system, with a primary focus on the three key pillars of biopharmaceuticals, new chemical drug formulations, in vitro diagnostic reagents, and high-end medical equipment. Additionally, they are committed to enhancing two distinctive industries -- special medical formula foods and animal healthcare products. Presently, the China Medical City has brought together over 1,300 healthcare companies, submitted applications for more than 2,100 pharmaceutical innovations, and attracted over 4,300 high-level talents for entrepreneurship. Taizhou has also become the exclusive pilot zone for the aggregation and development of the healthcare industry along the Yangtze Economic Belt and a pilot zone for the development of new vaccines and specific diagnostic reagents.

Key Points: 
  • TAIZHOU, China, Oct. 20, 2023 /PRNewswire/ -- On October 19, the 14th China (Taizhou) International Medical Expo commenced at the China Medical City Convention Trade Center.
  • Themed "Innovation Empowers the Construction of a Large Health Industry Ecosystem", this edition of the Medical Expo gathered nearly 130 industry experts from around the world.
  • Together, they collaborated to contribute to the development of Taizhou's healthcare industry, empowering Taizhou to establish itself as a global leader in the pharmaceutical and healthcare sector.
  • Throughout the duration of the Medical Expo, a total of 19 specialized events covering areas such as biopharmaceuticals, medical devices, health services, and international cooperation will invite participation from the public.

The 14th China (Taizhou) International Medical Expo Opens, Empowering the Growth of the Healthcare Industry

Retrieved on: 
Friday, October 20, 2023
CAS, Health, Vaccine, Aggregation, Entrepreneurship, University of the Chinese Academy of Sciences, Multilateralism, Chemical physics, Expo, Pharmaceutical industry

In recent years, Taizhou has set its sights on the goal of achieving a healthcare industry scale of 40 billion yuan by 2025, according to Taizhou Medical High-Tech Zone (Gaogang District). Emulating top domestic and international biopharmaceutical industry clusters, it has focused on constructing a distinctive "3+2" industrial system, with a primary focus on the three key pillars of biopharmaceuticals, new chemical drug formulations, in vitro diagnostic reagents, and high-end medical equipment. Additionally, they are committed to enhancing two distinctive industries -- special medical formula foods and animal healthcare products. Presently, the China Medical City has brought together over 1,300 healthcare companies, submitted applications for more than 2,100 pharmaceutical innovations, and attracted over 4,300 high-level talents for entrepreneurship. Taizhou has also become the exclusive pilot zone for the aggregation and development of the healthcare industry along the Yangtze Economic Belt and a pilot zone for the development of new vaccines and specific diagnostic reagents.

Key Points: 
  • TAIZHOU, China, Oct. 20, 2023 /PRNewswire/ -- On October 19, the 14th China (Taizhou) International Medical Expo commenced at the China Medical City Convention Trade Center.
  • Themed "Innovation Empowers the Construction of a Large Health Industry Ecosystem", this edition of the Medical Expo gathered nearly 130 industry experts from around the world.
  • Together, they collaborated to contribute to the development of Taizhou's healthcare industry, empowering Taizhou to establish itself as a global leader in the pharmaceutical and healthcare sector.
  • Throughout the duration of the Medical Expo, a total of 19 specialized events covering areas such as biopharmaceuticals, medical devices, health services, and international cooperation will invite participation from the public.